96 related articles for article (PubMed ID: 10232372)
1. Phosphorylation substrates and altered signalling in leukemias caused by BCR/ABL.
Groffen J; de Jong R; Haataja L; Kaartinen V; Heisterkamp N
Leukemia; 1999 Apr; 13 Suppl 1():S81-2. PubMed ID: 10232372
[No Abstract] [Full Text] [Related]
2. p210BCR/ABL induces formation of complexes containing focal adhesion proteins and the protooncogene product p120c-Cbl.
Salgia R; Sattler M; Pisick E; Li JL; Griffin JD
Exp Hematol; 1996 Feb; 24(2):310-3. PubMed ID: 8641358
[TBL] [Abstract][Full Text] [Related]
3. BCR/ABL-induced leukemogenesis causes phosphorylation of Hef1 and its association with Crkl.
de Jong R; van Wijk A; Haataja L; Heisterkamp N; Groffen J
J Biol Chem; 1997 Dec; 272(51):32649-55. PubMed ID: 9405482
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine phosphorylation of murine Crkl.
de Jong R; Haataja L; Voncken JW; Heisterkamp N; Groffen J
Oncogene; 1995 Oct; 11(8):1469-74. PubMed ID: 7478571
[TBL] [Abstract][Full Text] [Related]
5. STAP-2 interacts with and modulates BCR-ABL-mediated tumorigenesis.
Sekine Y; Ikeda O; Mizushima A; Ueno Y; Muromoto R; Yoshimura A; Kanakura Y; Oritani K; Matsuda T
Oncogene; 2012 Oct; 31(40):4384-96. PubMed ID: 22231445
[TBL] [Abstract][Full Text] [Related]
6. BCR/ABL signal transduction.
Tauchi T; Broxmeyer HE
Int J Hematol; 1995 Apr; 61(3):105-12. PubMed ID: 7599321
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway.
Dai Z; Quackenbush RC; Courtney KD; Grove M; Cortez D; Reuther GW; Pendergast AM
Genes Dev; 1998 May; 12(10):1415-24. PubMed ID: 9585502
[TBL] [Abstract][Full Text] [Related]
8. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
[TBL] [Abstract][Full Text] [Related]
9. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway.
Sattler M; Salgia R; Okuda K; Uemura N; Durstin MA; Pisick E; Xu G; Li JL; Prasad KV; Griffin JD
Oncogene; 1996 Feb; 12(4):839-46. PubMed ID: 8632906
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
Jilani I; Kantarjian H; Gorre M; Cortes J; Ottmann O; Bhalla K; Giles FJ; Albitar M
Leuk Res; 2008 Apr; 32(4):643-9. PubMed ID: 17900686
[TBL] [Abstract][Full Text] [Related]
11. Engagement of the CrkL adaptor in interferon alpha signalling in BCR-ABL-expressing cells.
Grumbach IM; Mayer IA; Uddin S; Lekmine F; Majchrzak B; Yamauchi H; Fujita S; Druker B; Fish EN; Platanias LC
Br J Haematol; 2001 Feb; 112(2):327-36. PubMed ID: 11167825
[TBL] [Abstract][Full Text] [Related]
12. C3G is tyrosine-phosphorylated after integrin-mediated cell adhesion in normal but not in Bcr/Abl expressing cells.
de Jong R; van Wijk A; Heisterkamp N; Groffen J
Oncogene; 1998 Nov; 17(21):2805-10. PubMed ID: 9840945
[TBL] [Abstract][Full Text] [Related]
13. Role of Dok-1 and Dok-2 in leukemia suppression.
Niki M; Di Cristofano A; Zhao M; Honda H; Hirai H; Van Aelst L; Cordon-Cardo C; Pandolfi PP
J Exp Med; 2004 Dec; 200(12):1689-95. PubMed ID: 15611295
[TBL] [Abstract][Full Text] [Related]
14. Molecular consequences of the BCR-ABL translocation in chronic myelogenous leukemia.
Sawyers CL
Leuk Lymphoma; 1993; 11 Suppl 2():101-3. PubMed ID: 8124222
[TBL] [Abstract][Full Text] [Related]
15. Role of the adapter protein CRKL in signal transduction of normal hematopoietic and BCR/ABL-transformed cells.
Sattler M; Salgia R
Leukemia; 1998 May; 12(5):637-44. PubMed ID: 9593259
[TBL] [Abstract][Full Text] [Related]
16. Characterization of p87C3G, a novel, truncated C3G isoform that is overexpressed in chronic myeloid leukemia and interacts with Bcr-Abl.
Gutiérrez-Berzal J; Castellano E; Martín-Encabo S; Gutiérrez-Cianca N; Hernández JM; Santos E; Guerrero C
Exp Cell Res; 2006 Apr; 312(6):938-48. PubMed ID: 16443220
[TBL] [Abstract][Full Text] [Related]
17. Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation.
Gishizky ML; Cortez D; Pendergast AM
Proc Natl Acad Sci U S A; 1995 Nov; 92(24):10889-93. PubMed ID: 7479904
[TBL] [Abstract][Full Text] [Related]
18. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
[TBL] [Abstract][Full Text] [Related]
19. The function of the pleckstrin homology domain in BCR-ABL-mediated leukemogenesis.
Demehri S; O'Hare T; Eide CA; Smith CA; Tyner JW; Druker BJ; Deininger MW
Leukemia; 2010 Jan; 24(1):226-9. PubMed ID: 19759561
[No Abstract] [Full Text] [Related]
20. [The Philadelphia chromosome: from the gene to therapeutic methods].
Pérez-Losada J; González-Sarmiento R; Sánchez-García I
Sangre (Barc); 1998 Apr; 43(2):127-35. PubMed ID: 9656774
[No Abstract] [Full Text] [Related]
[Next] [New Search]
